Sigma Biotech is a translational strategy firm integrating science, regulation, quality, and clinical execution into one coherent development framework.
All content and engagements are reviewed through Sigma’s internal quality and regulatory governance process.
Translational research bridges scientific discovery and real-world patient impact. It ensures innovations are developed in ways that can be safely tested, validated, approved, adopted, and sustained in clinical practice.
Sigma simplifies complex decisions by aligning evidence requirements, regulatory expectations, clinical feasibility, and operational execution early — when it matters most.
What We Help Simplify
Biotechnology most often fails not because of poor science, but because of misalignment across development functions.
Sigma exists to eliminate silos — aligning translational intent, regulatory reality, and clinical execution from the outset.
What ∑ Represents
Strategy anchored in regulatory pathways, clinical impact, and real-world use — not isolated milestones.
Regulatory, quality, clinical, and scientific leadership working as one unified team.
Alignment maintained from early strategy through post-market evidence generation.
Setting a record for the fastest enrolling clinical study and subsequent PMA approval — enabled by disciplined planning, feasibility alignment, and execution discipline.
Co-developer of the clinically validated SPOT GRADE bleeding severity scale — supporting consistent assessment and evidence quality.
Full leadership bios, credentials, and partner information are maintained on our Consultants & Partners page.
